Latest Content

Vistagen's fasedienol fails to show significant efficacy in treating social anxiety disorder, despite favorable safety data from the PALISADE-3 trial.

Explore innovative strategies for managing schizophrenia, focusing on novel treatments that address negative and cognitive symptoms beyond traditional antipsychotics.

Explore Irvin D. Yalom's impactful insights on psychotherapy, revealing the emotional dynamics between therapist and patient in transformative narratives.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

AI chatbots pose significant privacy risks as user data becomes proprietary, raising concerns about exploitation and data security in a digital landscape.

Explore the vital contributions of psychiatry, from therapeutic alliances to ethical principles, and the future challenges it faces in a complex world.

AFSP's new CAPS program empowers health care professionals with essential skills to identify and support patients at risk for suicide effectively.

Frank A. Clark, MD, reflects on current events using poetry.

Learn how to critically analyze randomized controlled trials to ensure trustworthy results and improve clinical decision-making in mental health care.

The article explores the psychological impact of recent mass killings, highlighting societal issues like anti-Semitism and mental health, while calling for collective healing.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.

Valproate's role in treating bipolar disorder is questioned as evidence suggests better alternatives exist for managing acute mania and maintenance.